The global adrenogenital syndrome treatment market will reach US$12.81 billion in 2023 and increase at a consistent compound yearly growth rate (CAGR) of 5.6% from 2023 to 2033. The reason for this growth is the increased emphasis on cutting-edge therapeutic approaches that enhance patient outcomes.
Hormonal abnormalities result from the genetic condition known as AGS, which affects the adrenal glands. The goal of treatment is to control these imbalances and reduce symptoms.
In Austria, newborn screening programs are designed to identify severe cases of AGS so that the afflicted children can be appropriately treated to prevent potentially fatal salt-wasting crises. One of the therapies offered as part of newborn screening programs is swap therapy. Since the symptoms of lesser variants, also known as non-classical AGS, manifest later in life and are less severe than those of classical AGS, they may go unnoticed for an extended period of time.
Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16420
It is anticipated that surgical correction of aberrant genital looks will further boost the market. The hormones that the adrenal glands are unable to produce are also replaced by hormonal therapy. Patients with long-term atopic illnesses are prescribed hydrocortisone or corticosteroids on a regular basis. The course of this medication is expected to normalize testosterone production.
Market Competition:
Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demands. To ensure that end users are able to benefit from the use of new products and technologies, you must promote them to end users. By forming a strategic partnership, a company can increase the amount of production it can do as a result of an increase in its capacity.
- Spruce Biosciences Inc. and Kaken Pharmaceutical Co. Ltd announced a licensing agreement to develop and commercialize Spruce’s product candidate, tildacerfont, for treating congenital adrenal hyperplasia (CAH). Spruce will receive a $15 million upfront payment from Kaken as part of the agreement, and additional payments are pending upon reaching future development and commercial milestones. In addition to that, tiers of double-digit royalties will be paid on Japanese net sales. For all other geographies, Spruce will retain all rights to tildacerfont, while Kaken will develop and market it in Japan.
- A new Phase 2 study from Neurorocrine Biosciences, Inc. is being presented demonstrating substantial reductions in adrenal androgens and androgen precursors in adolescent patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD). As part of its presentation in Hall A1, the company also provided information regarding patient preferences and treatment patterns for classic CAH.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16420
Key Companies Profiled:
- Crystal Pharma
- Monarch Pharmaceuticals, Inc.
- Jubilant Cadista Pharmaceuticals Inc.
- Pfizer CentreOne
- Healthkey Lifescience Pvt. Ltd.
- Zydus Pharmaceuticals
- Praxgen Pharmaceuticals
- Sandoz
- Vintage Labs
- Actavis, Inc.
Key Segments Profiled in the Adrenogenital Syndrome Treatment Market Industry Survey:
By Drug Type:
- Mineralocorticoids
- Glucocorticoids
By Route of Administration:
- Oral
- Parenteral
- Intravenous
- Inhaled
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Detailed Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16420
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube